Sanofi SA vs Wipro Limited — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Wipro Limited trades at $1.83 (market cap $18.49B). The key difference: Sanofi SA is far larger — about 5.7× Wipro Limited's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | WIT | |
|---|---|---|
Market Cap | $104.83B | $18.49B |
Sector | Health | Technology |
52-Week High | $52.34 | $3.06 |
52-Week Low | $41.33 | $1.82 |
Enterprise Value | $121.32B | $16.42B |
Dividend Yield | 5.5% | 4.68% |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →